Lantern Pharma (LTRN) Stock Price, News & Analysis

Company Overview

Lantern Pharma, Inc. is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need. Lead programs include LP-100, an alkylating agent advancing toward clinical evaluation in metastatic castration-resistant prostate cancer, and LP-184, a next-generation DNA-targeting compound in preclinical development for multiple solid tumors, including pancreatic and ovarian cancers. Lantern Pharma aims to streamline drug development timelines and reduce attrition rates by using AI-driven insights to inform preclinical and clinical strategies.

Lantern Pharma has established collaborations with institutions such as the National Cancer Institute’s Cancer Therapy Evaluation Program and academic partners to validate its platform and progress its candidates through regulatory pathways. The company’s approach blends computational analytics with traditional pharmacology, positioning Lantern to address the growing demand for precision oncology solutions. As it advances its pipeline, Lantern Pharma seeks to deliver new therapeutic options for patients and create long-term value through a data-driven development model.

Key Stats

• Today's Range: $3.90 to $4.19
• 50-Day Range: $1.98 to $4.17
• 52-Week Range: $1.11 to $5.74
• Volume: 64,881 shs
• Average Volume: 381,933 shs
• Market Capitalization: $50.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lantern Pharma Stock Analysis - MarketRank™

Lantern Pharma scored higher than 14% of companies evaluated by MarketBeat, and ranked 781st out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Lantern Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lantern Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lantern Pharma is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lantern Pharma is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lantern Pharma has a P/B Ratio of 6.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.72% of the float of Lantern Pharma has been sold short.

Short Interest Ratio / Days to Cover

Lantern Pharma has a short interest ratio ("days to cover") of 5.94.

Change versus previous month

Short interest in Lantern Pharma has recently decreased by 7.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lantern Pharma does not currently pay a dividend.

Dividend Growth

Lantern Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for LTRN on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Lantern Pharma in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $200,001.00 in company stock, which represents 0.3926% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Lantern Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $200,001.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

8.50% of the stock of Lantern Pharma is held by insiders.

Percentage Held by Institutions

28.62% of the stock of Lantern Pharma is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 7/06/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LTRN
• CIK: 1763950
• Web: www.lanternpharma.com
• Phone: 972-277-1136
• Fax: N/A
• Employees: 20
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($1.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.12 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -198.34%
• Return on Assets: -129.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.87
• Quick Ratio: 1.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: 6.78

Miscellaneous

• Outstanding Shares: 12,759,000
• Free Float: 11,674,000
• Market Cap: $50.21 million
• Optionable: Optionable
• Beta: 2.30